In conclusion, pharmacological intervention in the Wnt/β-catenin signaling with the CBP/β-catenin antagonist ICG-001 could inhibit tumor cell growth and migration, at least partially, via the miR-96/EVI1/miR-449a axis. The gene discussed is CREBBP; the disease is neoplasm.